Navigation Links
MiMedx Announces Its Support Of New CMS Packaging Payment Policy For Skin Substitutes
Date:11/29/2013

174; are 40 to 60 percent higher than the healing rates of our competitors' products.  Our strong clinical results and cost effective approach have enabled MiMedx to quickly gain market share. We believe the new reimbursement changes will enable us to continue that progress," added Bill Taylor, President and COO.

In the new system, CMS is dividing the skin substitutes into two groups for packaging purposes: high cost skin substitutes and low cost skin substitutes. Skin substitutes with an ASP amount above the weighted average of $32 per sq. cm. are classified in the high cost group and those at or below the weighted average per sq. cm. are classified in the low cost group.  The 2014 packaged rate for the low cost skin substitutes applied to DFUs and VLUs smaller than 100 sq. cm. is $409.41, and for the high cost skin substitutes is $1371.19.  As noted above, EpiFix® continues pass-through status for 2014, and it will be reimbursed on an ASP + 6% method.  It is worth noting that if EpiFix® were bundled in 2014, it would fall into the high cost packaged rate.

Taylor continued, "The size-appropriateness of our grafts, higher healing rates and fewer required applications to achieve wound closure have already enabled us to gain market share quickly. The DFU market for products such as EpiFix® is in excess of $2 billion annually.  Knowing that the VLU prevalence rate is nearly as high as the DFU rate, only with slightly larger wounds, we estimate the combined total DFU and VLU market for our EpiFix® products to be in excess of $4 billion annually.  To achieve our revenue guidance for 2014, we only need to capture 2.5% of that total possible DFU and VLU market, and that is excluding revenue from our other product lines."  

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and b
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
2. MiMedx Announces Record Third Quarter Results
3. MiMedx Reports On Meeting With FDA
4. MiMedx Responds To Misleading And Inaccurate Media Reports
5. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
6. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
7. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
8. MiMedx Announces Record Second Quarter Results
9. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
10. MiMedx To Exceed High End Of Second Quarter Guidance
11. MiMedx to Ring NASDAQ Stock Market Opening Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... 01, 2015 , ... A newly launched business plan contest will ask startup ... innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see ... a period of expert mentorship from a senior industry figure drawn from the Pistoia ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... (NASDAQ: AMGN ) today announced the submission of ... and Drug Administration (FDA) to expand the indication for XGEVA® ... the risk of developing bone metastases. If approved, XGEVA would ... spread of cancer to the bone. The ...
... June 27, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... arising out of a blog post on Friday, June ... the Company,s common stock fell more than 20% and ... (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The author of the blog ...
... Md., June 27, 2011 PharmAthene, Inc. (NYSE Amex: ... achieved an important technical milestone in its recombinant protective ... initial technology transfer of its manufacturing process for the ... the 100 liter scale to a US-based manufacturing facility ...
Cached Biology Technology:Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 2Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 3Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 4Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 5Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 6Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 7Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 8Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 9Generex Provides Clarification of Facts 2Generex Provides Clarification of Facts 3Generex Provides Clarification of Facts 4Generex Provides Clarification of Facts 5PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 2PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 3
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... 20 August 2010 - Pharma-Nutrition, the new international ... of scientific, technical and medical information products and ... and practical applications of medical nutrition in patient ... is set to take place next 18-20 April ...
... CHAPEL HILL Researchers at the University of North Carolina ... architecture controlling the growth of the collateral circulation the ... in the event of a heart attack or stroke. ... what are called collaterogenic therapies drugs or procedures that ...
... Four" Sherlock Holmes tells Watson he has written a monograph ... plates illustrating the difference in the ash." He finds the ... smoke during the commission of a crime. But Sherlock ... a patch on geologists and the "redox proxies" from which ...
Cached Biology News:Genetics underlie formation of body's back-up bypass vessels 2Geologists revisit the Great Oxygenation Event 2Geologists revisit the Great Oxygenation Event 3Geologists revisit the Great Oxygenation Event 4Geologists revisit the Great Oxygenation Event 5Geologists revisit the Great Oxygenation Event 6
... For rapid and efficient purification of DNA ... 15 minutes by gravity flow.Prepacked with Sephadex ... 0.15% Kathon CG/ICP Biocide.Available in three sizes ... (NAP-5), 1 ml (NAP-10) or 2.5 ml ...
Human Serpin A3 MAb (Clone 213907)...
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Mouse Semaphorin 6B MAb (Clone 256537)...
Biology Products: